{"success":true,"data":{"pressRelease":{"id":"11971","rtpr_id":"nNFC3JYD4c","ticker":"MEDP","exchange":"NASDAQ","all_tickers":["MEDP"],"title":"MEDP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026","author":"Newsfile Corp","published_at":"2026-04-28T23:22:17.741Z","article_body":"Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://api.newsfilecorp.com/redirect/wE0MzhBjO5) Encourages Investors Who\nSuffered Losses In Medpace To Contact Him Directly To Discuss Their Options\n\nIf you purchased or acquired securities in Medpace\n(https://api.newsfilecorp.com/redirect/gJRVKi5B2E) between April 22, 2025 and\nFebruary 9, 2026 and would like to discuss your legal rights, call Faruqi &\nFaruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.\n1310).\n\n[You may also click here for additional information]\n(https://api.newsfilecorp.com/redirect/ppgykh5YVg)\n\nNew York, New York--(Newsfile Corp. - April 28, 2026) - Faruqi & Faruqi, LLP\n(https://api.newsfilecorp.com/redirect/YEJQnhM0EQ), a leading national\nsecurities law firm, is investigating potential claims against Medpace\nHoldings, Inc. (\"Medpace\" or the \"Company\") (NASDAQ: MEDP) and reminds\ninvestors of the June 8, 2026 deadline to seek the role of lead plaintiff in a\nfederal securities class action that has been filed against the Company.\n\n(https://images.newsfilecorp.com/files/6455/294679_e6d3c491c4dd6a96_001full.jpg)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in New\nYork, Pennsylvania, California and Georgia. The firm has recovered hundreds of\nmillions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com.\n\nAccording to the complaint, defendants provided overwhelmingly positive\nstatements to investors while, at the same time, disseminating false and\nmisleading statements and/or concealing material adverse facts concerning the\ntrue state of Medpace's backlog cancellation rate. Defendants continuously\ntouted \"well behaved\" cancellation rates. Furthermore, Medpace made clear that\ncancellations were not caused by weak business or a weak funding environment,\nproviding investors with overly positive growth expectations that could not\nmaintain the projected 1.15 book-to-bill ratio.\n\nOn February 9, 2026, Medpace issued a press release announcing the Company's\nfourth quarter 2025 book-to-bill ratio of 1.04, well below the guidance of 1.\n15. Following this news, the price of Medpace's common stock declined\ndramatically. From a closing market price of $530.35 per share on February 9,\n2026, Medpace's common stock price fell to $446. 05 per share on February 10,\n2026, a decline of more than 15.9%.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nMedpace's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the Medpace class action, go to www.faruqilaw.com/MEDP or\ncall Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or\n212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/WAjq7UMprm), on X\n(https://api.newsfilecorp.com/redirect/qpg2PhKeGA), or on Facebook\n(https://api.newsfilecorp.com/redirect/nogW7cMqBr).\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or\npredict a similar outcome with respect to any future matter. We welcome the\nopportunity to discuss your particular case. All communications will be\ntreated in a confidential manner.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/294679","article_body_html":"","raw_payload":{"data":{"id":"nNFC3JYD4c","title":"MEDP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026","author":"Newsfile Corp","ticker":"MEDP","created":"2026-04-28T23:22:17.741Z","tickers":["MEDP"],"exchange":"NASDAQ","article_body":"Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://api.newsfilecorp.com/redirect/wE0MzhBjO5) Encourages Investors Who\nSuffered Losses In Medpace To Contact Him Directly To Discuss Their Options\n\nIf you purchased or acquired securities in Medpace\n(https://api.newsfilecorp.com/redirect/gJRVKi5B2E) between April 22, 2025 and\nFebruary 9, 2026 and would like to discuss your legal rights, call Faruqi &\nFaruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.\n1310).\n\n[You may also click here for additional information]\n(https://api.newsfilecorp.com/redirect/ppgykh5YVg)\n\nNew York, New York--(Newsfile Corp. - April 28, 2026) - Faruqi & Faruqi, LLP\n(https://api.newsfilecorp.com/redirect/YEJQnhM0EQ), a leading national\nsecurities law firm, is investigating potential claims against Medpace\nHoldings, Inc. (\"Medpace\" or the \"Company\") (NASDAQ: MEDP) and reminds\ninvestors of the June 8, 2026 deadline to seek the role of lead plaintiff in a\nfederal securities class action that has been filed against the Company.\n\n(https://images.newsfilecorp.com/files/6455/294679_e6d3c491c4dd6a96_001full.jpg)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in New\nYork, Pennsylvania, California and Georgia. The firm has recovered hundreds of\nmillions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com.\n\nAccording to the complaint, defendants provided overwhelmingly positive\nstatements to investors while, at the same time, disseminating false and\nmisleading statements and/or concealing material adverse facts concerning the\ntrue state of Medpace's backlog cancellation rate. Defendants continuously\ntouted \"well behaved\" cancellation rates. Furthermore, Medpace made clear that\ncancellations were not caused by weak business or a weak funding environment,\nproviding investors with overly positive growth expectations that could not\nmaintain the projected 1.15 book-to-bill ratio.\n\nOn February 9, 2026, Medpace issued a press release announcing the Company's\nfourth quarter 2025 book-to-bill ratio of 1.04, well below the guidance of 1.\n15. Following this news, the price of Medpace's common stock declined\ndramatically. From a closing market price of $530.35 per share on February 9,\n2026, Medpace's common stock price fell to $446. 05 per share on February 10,\n2026, a decline of more than 15.9%.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nMedpace's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the Medpace class action, go to www.faruqilaw.com/MEDP or\ncall Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or\n212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/WAjq7UMprm), on X\n(https://api.newsfilecorp.com/redirect/qpg2PhKeGA), or on Facebook\n(https://api.newsfilecorp.com/redirect/nogW7cMqBr).\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or\npredict a similar outcome with respect to any future matter. We welcome the\nopportunity to discuss your particular case. All communications will be\ntreated in a confidential manner.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/294679"},"type":"article","timestamp":"2026-04-28T23:22:17.786854642Z","server_sent_at_ms":1777418537786},"received_at":"2026-04-28T23:22:49.211Z","source_url":"https://www.newsfilecorp.com/release/294679"},"analysis":{"id":"9292","press_release_id":"11971","analysis_json":{"industry":{"label":"Health Care Equipment & Services","sector":"Health Care"},"redFlags":["Securities class action filed alleging concealment of material adverse facts regarding backlog cancellation rates","15.9% single-day stock decline following missed book-to-bill guidance"],"eventType":"legal_litigation","narrative":"Faruqi & Faruqi reminded investors of the June 8, 2026 deadline to seek lead plaintiff status in a federal securities class action against Medpace.\n\nThe lawsuit alleges that Medpace made misleading statements about its backlog cancellation rates while projecting growth that could not be maintained.\n\nThe claims follow a February 9, 2026 disclosure that the book-to-bill ratio was 1.04, missing guidance of 1.15, which preceded a 15.9% stock decline.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"Lawsuit alleges Medpace hid cancellation weakness before 16% stock drop."},"keyFigures":{"customDimensions":{"book_to_bill_guidance":1.15,"stock_decline_percent":"15.9%","book_to_bill_ratio_q4_2025":1.04}},"quotedText":"defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements","namedEntities":{"people":[{"name":"Josh Wilson","role":"Partner"}],"products":[],"companies":[{"name":"Medpace Holdings, Inc.","ticker":"MEDP"},{"name":"Faruqi & Faruqi, LLP","relationship":"plaintiff counsel"}],"dollarAmounts":[{"amount":"$530.35","context":"closing market price on February 9, 2026"},{"amount":"$446.05","context":"stock price on February 10, 2026"}]},"materialImpact":{"score":2,"reasoning":"This is a routine 'deadline reminder' press release from a law firm regarding a class action lawsuit. While the underlying allegations involve a significant 15.9% stock drop, the announcement itself is a standard procedural notice."},"tickerRelevance":{"others":[],"primary":"MEDP"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"legal_deadline_reminder","sectorWeight":"healthcare","marketCapAdjustment":"mid"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":2,"narrative":"Faruqi & Faruqi reminded investors of the June 8, 2026 deadline to seek lead plaintiff status in a federal securities class action against Medpace.\n\nThe lawsuit alleges that Medpace made misleading statements about its backlog cancellation rates while projecting growth that could not be maintained.\n\nThe claims follow a February 9, 2026 disclosure that the book-to-bill ratio was 1.04, missing guidance of 1.15, which preceded a 15.9% stock decline.","key_figures":{"customDimensions":{"book_to_bill_guidance":1.15,"stock_decline_percent":"15.9%","book_to_bill_ratio_q4_2025":1.04}},"named_entities":{"people":[{"name":"Josh Wilson","role":"Partner"}],"products":[],"companies":[{"name":"Medpace Holdings, Inc.","ticker":"MEDP"},{"name":"Faruqi & Faruqi, LLP","relationship":"plaintiff counsel"}],"dollarAmounts":[{"amount":"$530.35","context":"closing market price on February 9, 2026"},{"amount":"$446.05","context":"stock price on February 10, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-29T00:36:12.359Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"mid-cap","eventGravity":"legal_deadline_reminder","sectorWeight":"healthcare","marketCapAdjustment":"mid"}},"durationMs":102971,"modelName":"glm-4.7"}}